Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc (CNTA) Revenue
Annual & quarterly revenue history · segment & region breakdown
CNTA · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCentessa Pharmaceuticals plc trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | — |
| 2024-12-31 | $0.00B | -$0.01B | -100.00% |
| 2023-12-31 | $0.01B | +$0.01B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare CNTA revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Centessa Pharmaceuticals plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Centessa Pharmaceuticals plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Centessa Pharmaceuticals plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CNTA revenue · 4 questionsCNTA's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Centessa Pharmaceuticals plc SEC filings · GAAP · Centessa Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026